CTOs on the Move


 
Apotex is the largest Canadian owned pharmaceutical company, and the largest producer of generic medicines in the country. Founded in 1974, Apotex has steadily grown to employ over 10,000 people around the world, focused on research, development, manufacturing and distribution.
  • Number of Employees: 5K-10K
  • Annual Revenue: $50-100 Million
  • www.apotex.com
  • 150 Signet Drive
    Toronto, ON CAN M9L 1T9
  • Phone: 800.268.4623

Executives

Name Title Contact Details

Similar Companies

Michael's Pharmacy

Michael's Pharmacy is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caravel Autism Health

Caravel Autism Health provides early intervention to treat signs & symptoms of Autism. We serve families in Green Bay, Milwaukee, Madison, Wausau & Chicago.

International Partnership for Microbicides

Developing HIV prevention products for women worldwide

Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as the Mayo Clinic and Dartmouth College, and develops those programs from bench to commercial applications.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.